Skip To Main Content
Jacqueline C Barrientos on Muck Rack

Jacqueline C Barrientos

As seen in: Nature, Wiley Online Library, MDPI, The Lancet, Healio, American Journal of Managed Care, HMP Global Learning Network, The Journal of Immunology, Future Medicine, OncLive and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jacqueline C

Contact Jacqueline C, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease

|
By Michael Choi, Emanuela M Ghia, Tanya Siddiqi, Jacqueline C Barrientos, Joseph M. Tuscano, Jean L. Koff, Lori A. Leslie, Nicole Lamanna, Gina Chung, James Robinson, Susan O’Neill Verified, Catriona Jamieson, William Wierda, Thomas Kipps, Salim Yazji, Iris Isufi, Alec Goldenberg, Suki Subbiah, James B. Breitmeyer
| Nature Verified
Abstract The receptor tyrosine kinase‑like orphan receptor (ROR1) is aberrantly expressed on chronic lymphocytic leukemia (CLL) cells and promotes survival signaling through NF‑κB, ERK1/2, and mTORC1. Zilovertamab is a humanized monoclonal antibody targeting ROR1. We conducted a multicenter phase 1b/2 study of zilovertamab plus ibrutinib (Z + I) in relapsed/refractory CLL. Phase 1b/2a (N = 34) established a recommended zilovertamab dose based on safety, pharmacokinetics, and ROR1 occupancy.
Open in Who Shared Issue with article?

Combination Treatment Strategies for Patients With Chronic Lymphocytic Leukemia

|
By Jacqueline C Barrientos
| Oncology Learning Network Verified
At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Jacqueline Barrientos, MD,  Mount Sinai Medical Center, Miami, Florida, discusses emerging combination treatment strategies in chronic lymphocytic leukemia (CLL). Dr Barrientos highlights the growing role of Bruton's tyrosine kinase (BTK) inhibitor-based doublet and triplet regimens and the evolving use of minimal residual disease (MRD) to guide treatment duration and sequencing.
Open in Who Shared Issue with article?

Latest Insights Into Marginal Zone Lymphoma Management and Treatment

|
By Jacqueline C Barrientos
| Oncology Learning Network Verified
At the 2026 Leukemia, Lymphoma & Myeloma Symposium (LL&M) Winter Symposium in Amelia Island, Florida, Jacqueline Barrientos, MD, MS, Mount Sinai Medical Center, Miami, Florida presented on new clinical insights in marginal zone lymphoma. Transcript: My name is Jacqueline Barrientos. I'm the chief of hematologic malignancies and director of oncological research at Mount Sinai Medical Center in Miami Beach.
Open in Who Shared Issue with article?
See all 15 licensed articles (46 Total)